Proteogenomic analysis of clonal and cellular architecture in 2 patients treated with tagraxofusp on the clinical trial. (A) Clonal architecture and its evolution in 2 patients whose best response was SD at 2 time points: before treatment on cycle 1 day 1, and after treatment on cycle 4 day 29. (B) Individual cell types as identified by surface protein expression using 42 oligo-conjugated cell surface markers at 2 time points: before treatment on cycle 1 day 1, and after treatment on cycle 4 day 29. Mono, monocyte; NGS, next-generation sequencing; NK, natural killer; pDC, plasmacytoid dendritic cell; UMAP, uniform manifold approximation and projection.